Oseltamivir resistance: What does it mean clinically?

Clinical Infectious Diseases

Volumn 49, Issue 12, 2009, Pages 1836-1837

  Baum, Stephen G ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

FEVER; HIGH RISK PATIENT; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MORTALITY; NONHUMAN; NOTE; PANDEMIC; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS SHEDDING;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; OSELTAMIVIR;

EID: 72049097920     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648425     Document Type: Note

References (2)

1. Kawai N, Ikematsu H, Hirotsu N, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009; 49: 1828-1835 (in this issue).
2. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A(H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-972